New Zealand patients have a higher melanoma burden in sentinel nodes and completion lymphadenectomy than patients in MSLT-II
Journal of Plastic, Reconstructive & Aesthetic Surgery · 2023
DOI: 10.1016/j.bjps.2023.04.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Plastic, Reconstructive & Aesthetic Surgery, 2023. Verfasst von Tea Stuart Williams und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Tauranga Hospital, Tauranga, New Zealand. Hauptthemen laut MEDLINE: Melanoma, Sentinel Lymph Node, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
New Zealand has the highest rate of melanoma-related mortality in the world. Access to immunotherapy and radiology is limited and surgical treatment of regional disease remains important. A recent pilot study of a single health district observed a higher nodal melanoma burden than was reported in the second Multicentre Selective Lymphadenectomy Trial (MSLT-II). In this study, a series of regional censuses were undertaken covering the 10 years immediately prior to the publication of MSLT-II. The study population was seven District Health Boards covering 62.2% of the population of New Zealand across a 10-year period preceding MSLT-II. The primary outcomes measured were the size of sentinel lymph node metastases and non-sentinel node (NSN) positivity on completion lymph node dissection (CLND) for patients with a positive sentinel lymph node biopsy (SLNB). In the 2323 SLNB identified, the mean sentinel lymph node metastatic deposit size was larger compared to MSLT-II (2.55 vs. 1.07/1.11 mm). A greater proportion of New Zealand patients (44.2%) had metastatic deposits larger than 1 mm compared to MSLT-II (33.2/34.5%) and the rate of non-sentinel node involvement on CLND was also higher (22.2% vs. 11.5%). These findings indicate that New Zealand is a high-risk population for nodal melanoma metastases. Due to these differences, the conclusions of MSLT-II may not be able to be applied to melanoma patients in the 7 regions studied in New Zealand.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Tauranga Hospital, Tauranga, New Zealand.
- Department of Surgery, Tauranga Hospital, Tauranga, New Zealand. Electronic address: brandon.adams@actrix.co.nz.
Zitieren
APA
Williams, T. S., Arahill-Whitham, J., Bailey, T. A., Hayward, G., Li, A., Tallon, B., Wen, D., & Adams, B. M. (2023). New Zealand patients have a higher melanoma burden in sentinel nodes and completion lymphadenectomy than patients in MSLT-II. Journal of Plastic, Reconstructive & Aesthetic Surgery. https://doi.org/10.1016/j.bjps.2023.04.019
Vancouver
Williams TS, Arahill-Whitham J, Bailey TA, Hayward G, Li A, Tallon B, et al. New Zealand patients have a higher melanoma burden in sentinel nodes and completion lymphadenectomy than patients in MSLT-II. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2023. doi:10.1016/j.bjps.2023.04.019
BibTeX
@article{Williams2023,
author = {Williams, Tea Stuart and Arahill-Whitham, Jacob and Bailey, Teresa A and Hayward, Greg and Li, Alexandra and Tallon, Ben and Wen, Daniel and Adams, Brandon Michael},
title = {New Zealand patients have a higher melanoma burden in sentinel nodes and completion lymphadenectomy than patients in MSLT-II},
journal = {Journal of Plastic, Reconstructive & Aesthetic Surgery},
year = {2023},
doi = {10.1016/j.bjps.2023.04.019}
}
EUVIMED